Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTIID)
Date:9/19/2007

Q4/07 Review Issued by Scimitar Equity Research, Inc.

BOSTON, Sept. 19 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (Nasdaq: NTIID), entitled, "The Secret of Success is Constancy of Purpose: VIPRINEX(TM) Could Restore Stroke Patients to Fuller Lives and They Will Be the Real Miracle of NTII's Achievement".

This review is available at our website: http://www.scimitarequity.com.

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTIID is focused on therapies for neurological conditions that occur in connection with ischemic stroke, brain cancer, Alzheimer's disease and dementia. NTIID's strategy is to in-license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTIID's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. For further information, please visit NTII's website at http://www.ntii.com.

NTII's common stock will trade under the symbol "NTIID" for 20 trading days to denote the recent reverse (7 for 1) split. After that time, the symbol will revert back to "NTII". Holders of record will be receiving instructions from NTII's transfer agent to define the procedures of surrendering their pre-split share certificates as well as assign their receipt of the new post-split certificates. NTIID's primary objective in authorizing the reverse split is to raise the share trading price of its common stock and to increase the number of shares of authorized but un-issued common stock.

Scimitar Equity Research, Inc. provides sponsored equity research of the health sciences industry for the institutional and investment co
'/>"/>

SOURCE Scimitar Equity Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ... the housing market remaining soft. , This solid economic news ...
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , LAUSANNE, Switzerland and ... Swiss-based global biopharmaceutical group,of companies with a focus ... medical needs, and MSM Protein Technologies (MSM), a ... in targeting,multi-spanning membrane proteins, announce the signature of ...
... ... standard gas stick that can be shipped from stock greatly minimizing lead times for ... ... based firm specializing in process controls for the delivery of critical fluids, introduces an ...
... class of economically viable solar power cellscheap, flexible and ... as a result of recent work* at the National ... deepened their understanding of the complex organic films at ... rely on organic molecules to capture sunlight and convert ...
Cached Biology Technology:Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 3Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 4Aztech Controls Introduces Standardized Gas Sticks for Semiconductor Tool Hook Up 2Aztech Controls Introduces Standardized Gas Sticks for Semiconductor Tool Hook Up 3NIST scientists study how to stack the deck for organic solar power 2
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... at the University of Liverpool have discovered that the ... million years old and took its present shape about ... in collaboration with the University of Amsterdam and Petrobras, ... taken from two boreholes near the mouth of the ...
... well-fed, clonal organisms in the Caribbean Sea as the ... Pacific, report researchers from the Smithsonian Tropical Research Institute ... shows that if a species could shift from clonal ... for extinction, millions of years later. Closure of the ...
... A study conducted by researchers at Ben-Gurion University of the ... indicates that approximately 16 percent of public health care workers ... regardless of the severity. The study,just published in the ... 1,835 public health workers in Minnesota, Ohio and West Virginia ...
Cached Biology News:Sex in the Caribbean: Environmental change drives evolutionary change -- eventually 21 in 6 health workers won't report in flu pandemic -- study by Ben-Gurion U. researchers 21 in 6 health workers won't report in flu pandemic -- study by Ben-Gurion U. researchers 3
... BTX, the leader in electroporation products and ... innovative product line for experiment optimization and ... is a breakthrough in Molecular Delivery. The ... procedures that typically limited the number of ...
...
... analysis standard is a lyophilized ... molecular weights range from 69 ... provided for use with the ... organic acid analysis kit for ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Biology Products: